Clinical Trial: A Phase 1 Study of VELA-101 in Adult Participants

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07864311) titled 'A Phase 1 Study of VELA-101 in Adult Participants' on Oct. 02.

Brief Summary: This is a first-in-human (FIH), multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VELA-101, following single-ascending doses via subcutaneous (SC) administration.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Healthy Participants Hyperlipidemia

Intervention: DRUG: VELA-101

subcutaneous injection

DRUG: Placebo

subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ursa Medicines

Disclaimer: Curated by HT Synd...